Sangamo Therapeutics filed for Chapter 11 bankruptcy and lined up asset-sale agreements with Eli Lilly and Astellas as stalking horse bidders. The agreements cover Sangamo’s capsid delivery platform, zinc finger nuclease (ZFN) platform, modular integrase (MINT) platform, and its prion disease program ST-506; Astellas would acquire the Fabry disease gene therapy program, isaralgagene civaparvovec (ST-920). Sangamo said the stalking horse bids do not include several other programs, including ST-503 for chronic neuropathic pain, giroctocogene fitelparvovec for hemophilia A, and certain cell therapy and regulatory T cell (Treg) assets. Those remaining assets are expected to remain available to other bidders at auction. The move follows years of clinical and financing headwinds and underscores how quickly gene-editing platform value can be repriced when pipeline execution stalls. Sangamo framed the process as a disciplined, value-maximizing sale process while supporting stakeholders through the proceedings.